Heart failure & cardiomyopathiesCohort study
Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device—a real-world, single-centre, observational study
- real-world, single-centre, observational study
Authors' conclusion
Long-term survival on HeartMate 3 LVAD support exceeded 60% at 5 years in this single-centre cohort. While adverse events such as device related infections and heart failure hospitalizations continue to pose a substantial clinical challenge, the incidence of thrombotic complications was low, underscoring improvement in clinical outcomes with current generation centrifugal LVAD devices.
Study context
- Population
- Patients implanted with a HeartMate 3 left ventricular assist device (LVAD) at the University Medical Center Groningen (UMCG) between 2016 and 2025patients implanted with a HeartMate 3 LVAD
- Participants
- 176 patients
- Exposure
- Outcomes stratified according to LVAD treatment strategy
- Outcome
- On device survival
Main finding
As reported in the abstract
Overall survival at 1 year
87%
Overall survival at 2 years
82%
Overall survival at 5 years
61%
Observational data: associations, not effects.
Secondary outcomes
Baseline characteristics
- Mean age at implantation
- 56 ± 11 years
- Female
- 26%
Safety
Major adverse events
- Device-related infections, events per patient-year at risk
- 0.29
- Heart failure hospitalizations, events per patient-year at risk
- 0.18
- Device dysfunction, events per patient-year at risk
- 0.04
- Cerebrovascular events, events per patient-year at risk
- 0.02
- No LVAD pump thrombosis events were recorded
Original publication
Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device—a real-world, single-centre, observational study. ESC Heart Fail. Published 11 March 2026. doi:10.1093/eschf/xvag074
Summarised from the published abstract; every number is checked against it